SLC5A2 and Hepatic steatosis: Hepatic triglyceride content is closely associated with steatosis in NASH as well as with de novo lipogenesis [66], therefore, SGLT2 inhibitors may have potential therapeutic efficacy in T2DM-associated hepatic steatosis.